Clinical trialNCT04317534RecruitingPhase 2Interventional

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

SponsorGreg Durm, MDEnrollment244NSCLC, Stage I

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm. Patients will be randomized (1:1) 4-12 weeks following surgery to either: * Arm A: Pembrolizumab 400 mg every 6 weeks × 9 cycles * Arm B: Observation Stratification factors will include: PD-L1 TPS (\<50% vs. ≥50%), and tumor size (1-2 cm vs. \>2-4 cm)

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Greg Durm, MD
Indiana University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Moffit Cancer Center
Tampa, Florida, United States
Alberto Chiappori, MD
Recruiting
University of Illinois Cancer Center
Chicago, Illinois, United States
Lawrence Feldman, MD
Recruiting
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
Greg Durm, MD
Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Muhammad Furqan, MD
Recruiting
University of Minnesota
Minneapolis, Minnesota, United States
Amit Kulkarni, MD
Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, United States
Apar Ganti, MD
Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Missak Haigentz, MD
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Dwight Owen, MD
Recruiting
Providence Health & Services - Oregon
Portland, Oregon, United States
Rachel Sanborn, MD
Recruiting
Penn State Cancer Institute
Hershey, Pennsylvania, United States
Patrick Ma, MD
Recruiting
University of Virginia Health System
Charlottesville, Virginia, United States
Richard Hall, MD
Recruiting
Virginia Commonwealth University
Richmond, Virginia, United States
Rachit Shah, MD
Recruiting
Univeristy of Wisconsin
Madison, Wisconsin, United States
Anne Traynor, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 May 2020
Primary completion: 8 Apr 2027
Completion: 8 Apr 2028
Last update posted: 5 May 2026
Registered enrollment: 244
Registry id: NCT04317534

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.